Document is current
Any future updates will be listed below
-
Authors
Wellner, Alon
McMahon, Conor
Gilman, Morgan S. A.
Clements, Jonathan R.
Clark, Sarah https://orcid.org/0000-0001-9944-0919
Nguyen, Kianna M.
Ho, Ming H.
Hu, Vincent J. https://orcid.org/0000-0001-8580-067X
Shin, Jung-Eun
Feldman, Jared
Hauser, Blake M.
Caradonna, Timothy M. https://orcid.org/0000-0001-7138-4441
Wingler, Laura M. https://orcid.org/0000-0002-3688-5088
Schmidt, Aaron G. https://orcid.org/0000-0003-3627-2553
Marks, Debora S.
Abraham, Jonathan
Kruse, Andrew C. https://orcid.org/0000-0002-1467-1222
Liu, Chang C. https://orcid.org/0000-0002-3290-2880
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (T32GM007753, T32GM007753, T32GM007753, R01AI146779, 1R01CA260415, DP5OD021345, 1R01CA260415, 1R35GM136297, 1R01CA260415)
Massachusetts Consortium on Pathogenesis Readiness
Vallee Foundation (Scholars Award)
Gordon and Betty Moore Foundation (Inventors Fellowship)
UC | University of California, Irvine (COVID-19 Basic, Translational and Clinical Research Fund)
- License Information
-
More Information
Article History
Received: 6 March 2021
Accepted: 11 June 2021
First Online: 24 June 2021
Competing interests
: Provisional patents (US Patent Application No. 63/123,558 and US Patent Application No. 63/111,860) have been filed on this work. A.C.K. is a co-founder and advisor of Tectonic Therapeutic, Inc., and of the Institute for Protein Innovation. C.C.L. is a co-founder of K2 Biotechnologies, Inc., which focuses on the use of continuous evolution technologies applied to antibody engineering.
